The memory of mice with Alzheimer's greatly improved after they were injected with two newly discovered short peptides.
List view / Grid view
Filter the results
Chronic inflammatory processes in ageing brains lead to lymphoma cells that have entered the brain tissue being retained.
A new platform has enabled an unprecedented level of control over individual molecules and particles on a chip for high-throughput analysis.
A new study has found a small molecule which prevents cancer cells from mutating and becoming resistant to chemotherapy.
Small molecule drug discovery has long been the domain of pharmaceutical companies, and that’s not likely to change anytime soon. But there’s a cadre of universities and nonprofit research institutes that have embraced drug development at its earliest stages, in some cases identifying and optimising compounds that target possible disease-driving…
Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
Webinar highlights: Recent advances in diagnostics and treatments – from small molecules to cellular therapies
The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.
The Small Molecule Screening Facility (SMSF) at the University of Wisconsin Madison is a comprehensive high-throughput screening (HTS) centre where researchers have investigated antibiotic-resistant bacterial infections and screening for protein-protein interactions using HTS methods.
For drug discovery and biomarker research, screening campaigns are employed to identify potential new treatments for diseases and to answer questions that remain unknown in the scientific community.
Contract Research Organisations rely on microplate readers for effective hit discovery. Ian Waddell, of Charles River Laboratories, explains what his needs are.
30 October 2018 | By BMG Labtech GmbH
In this webinar, we presented two examples of HTS in 1536-well plates, a screen for protein-protein interactions and a cell-based luciferase reporter assay.
Integrated fragment-based approach reveals enzymatic inhibitors with potential therapeutic application
25 October 2018 | By NanoTemper Technologies
In this webinar, speakers presented results of integrated fragment-based approaches that have led to the discovery of the first ligands of IDO1 that are able to modulate non-catalytic signalling functions of the enzyme...